Global Gastric Cancer Treatment Market - Growth, Trends and Forecasts 2017 - 2022

  • ID: 4388559
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 4
The global gastric cancer therapeutics market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX million in 2015 and is forecasted to reach USD XX million by 2021.

The National Cancer Institute reports an estimated 26370 new cases and 10730 deaths in 2016, due to gastric cancer in the U.S. The launch of premium-priced treatment for the advanced or metastatic disease, such as anti-angiogenesis and HER2-targeted therapies, are expected to propel the market during the forecast period. Key patents of Roche’s Herceptin, the leading drug in gastric cancer treatment, since its launch in 2010, expired during 2014-2015 in the 5EU, Japan and China; expected to expire in the US in 2019. However, Roche is expected to remain a strong player in the gastric cancer market, with its new therapy Perjeta in the pipeline.

Global Gastric Cancer Therapeutics - Market Dynamics

The report details several factors driving and restraining the market, some of which are discussed below.


Increasing incidence of adenocarcinoma, lymphoma and gastrointestinal stromal tumors

Increased usage of combination therapies

Large number of regulatory approvals for metastatic gastric cancer

Low dose radiation technology-based devices


Lack of health insurance policies

Stringent regulatory guidelines

Market Segmentation

The global gastric cancer therapeutics market has been segmented by type of treatment and end-users. The treatment segment is further segmented into surgery, targeted drugs therapy (Sunitinib, Trastuzumab, Imatinib), chemotherapy (5-flourouracil, Capecitabine, Carboplatin, Cisplatin, Epirubicin, Irinotecan, Oxaliplatin, Paclitaxel), adjuvant chemotherapy and radiation therapy. The end-users segment consists of hospitals, clinics, specialized cancer treatment centers and ambulatory surgical centers. The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.

Major Companies in the Sector Include:

This Report Offers:

Market definition, along with identification of key drivers and restraints for the market.

Market analysis with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.

An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.
Note: Product cover images may vary from those shown
2 of 4
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
1.7 Report Description
2.1 Introduction
2.2 Analysis Methodology
2.3 Study timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
5.1 Current Market Scenario
5.2 Market Overview
5.3 Porters Five Force Analysis
5.3.1 Bargaining Power Of Suppliers
5.3.2 Bargaining Power Of Buyers
5.3.3 Degree Of Competition
5.3.4 Threat Of Substitution
5.3.5 Threat Of New Entrants
6.1 Market Drivers
6.1.1 Increasing Incidence of Adenocarcinoma, Lymphoma and Gastrointestinal Stromal Tumors
6.1.2 Increased Usage of Combination Therapies
6.1.3 Large Number of Regulatory Approvals for Metastatic Gastric Cancer
6.1.4 Low-Dose Radiation Technology Based Devices
6.2 Market Restraints
6.2.1 Lack of Health Insurance Policies
6.2.2 Stringent Regulatory Guidelines
6.3 Market Opportunities
6.4 Key Challenges
7. Global Gastric Cancer Treatment Market - Segmentation
7.1.1 Surgery
7.1.2 Targeted Drugs Therapy Sunitinib (Sutent) Trastuzumab (Herceptin) Imatinib (Gleevec)
7.1.3 Chemo Therapy 5-flourouracil Capecitabine Carboplatin Cisplatin Epirubicin Irinotecan Oxaliplatin Paclitaxel
7.1.4 Adjuvant Chemotherapy
7.1.5 Radiation Therapy
7.2.1 Hospitals
7.2.2 Clinics
7.2.3 Specialized Cancer Treatment Centers
7.2.4 Ambulatory Surgical Centers
8. Global Gastric Cancer Treatment Market - Regional Shares and Forecast
8.1 North America
8.1.1 United States
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 UK
8.2.3 France
8.2.4 Italy
8.2.5 Spain & Portugal
8.2.6 Scandinavia
8.2.7 Benelux
8.2.8 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 The Middle East and Africa
8.4.1 GCC
8.4.2 South Africa
8.4.3 Rest of the Middle East and Africa
8.5 Latin America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 Eli Lilly
10.2 F. Hoffmann-La Roche Ltd
10.3 GlaxoSmithKline plc
10.4 Merck KGaA
10.5 Otsuka Holdings Co. Ltd
10.6 BMS
10.7 Pfizer
10.8 Sanofi
10.9 Others
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 4


4 of 4
Note: Product cover images may vary from those shown